Valeo Pharma logo

Valeo Pharma(OTC) VPHIF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-100%
1 Month+0%
$0.00
+0.00%
+0.00Today
Valeo Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-28
Valeo Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-11
1 month+0%USD 0.002026-07-15
3 month+0%USD 0.002026-02-11
Year to date-99%USD 0.002025-12-31
1 year-100%USD 0.052024-09-30
3 year-100%USD 0.162023-09-29
5 year-100%USD 0.622021-09-29
Since inception-100%USD 0.832020-09-23

Valeo Pharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$53.38M

Net Income (TTM)

-CA$32.12M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.04 (Low)

Price

$0.00

Volume

1,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Sep 30, 2026

VPHIF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Valeo Pharma

Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm focused on sourcing, licensing, and selling a diverse range of medicinal products. The company emphasizes respiratory, specialized, and hospital-grade generic drugs, catering to various medical needs.

Products and Services
  • Prominent asthma medications: Enerzair Breezhaler and Atectura Breezhaler
  • Redesca for preventing deep vein thrombosis and pulmonary embolism
  • Onstryv for Parkinson's Disease and M-Eslon for pain management
Growth Outlook
  • Recent quarterly revenue of CAD 12.6 million shows potential for growth
  • Strong product pipeline with multiple therapeutic areas addressed
  • Focus on expanding market presence in specialty pharmaceuticals
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 49.5 million indicates steady performance
  • Operating income margin improved to -25.5% in the latest quarter
  • Cash and cash equivalents reached CAD 7.1 million, supporting operational needs
Valeo Pharma Inc. operates in the healthcare sector, specifically within the drug manufacturing industry. The company has established a diverse portfolio of products that address critical health issues, particularly in respiratory and neurological conditions. Recent financial performance indicates a revenue increase, reflecting the company's ability to capture market demand. The focus on specialty pharmaceuticals positions Valeo for potential growth, especially as it continues to expand its product offerings and market reach. The financial metrics suggest a commitment to improving operational efficiency, which may enhance profitability in the future. Investors may find Valeo Pharma Inc. an intriguing opportunity within the pharmaceutical landscape.
AI Generated • Sep 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

125

CEO

Steven Saviuk, CPA

Website

www.valeopharma.com

Headquarters

Kirkland, QC H9H 4R9, CA

VPHIF Financials

Key Financial Metrics (TTM)

Gross Margin

24.26%

Operating Margin

-31.96%

Net Income Margin

-51.58%

Return on Equity

95.58%

Return on Capital

-69.38%

Return on Assets

-67.48%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

1.00K

Avg. Volume

53.908

Financials (TTM)

Gross Profit

CA$8.92M

Operating Income

-CA$19.11M

EBITDA

-CA$15.96M

Operating Cash Flow

-CA$4.28M

Capital Expenditure

-CA$5.12M

Free Cash Flow

-CA$9.40M

Cash & ST Invst.

CA$7.13M

Total Debt

CA$70.08M

Valeo Pharma Performance Analysis

Valeo Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-10-31CAD 10,778,261N/A
20222022-10-31CAD 21,542,13799.9%
20232023-10-31CAD 39,970,52185.5%
Valeo Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-10-31-6.9%
Q12024-01-313.3%
Q22024-04-304.4%
Q32024-07-31-10.8%
Valeo Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-10-31CAD -0.16N/A
20222022-10-31CAD -0.2552.8%
20232023-10-31CAD -0.24-3.2%
Valeo Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-10-31-42.3%
Q12024-01-3118.8%
Q22024-04-300.8%
Q32024-07-31-4.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

CA$12.60M

-10.5%

Gross Profit

CA$3.43M

-19.6%

Gross Margin

27.25%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

70

N/A

Net Income

-CA$8.19M

-40.3%

EBITDA

-CA$3.68M

-109.7%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

CA$7.13M

-27.1%

Total Debt

CA$70.08M

+9.3%

Accounts Receivable

CA$4.78M

-5.4%

Inventory

CA$4.94M

-61.7%

Long Term Debt

CA$24.44M

-61.8%

Short Term Debt

CA$45.65M

+36474.0%

Return on Assets

-67.48%

N/A

Return on Invested Capital

-82.30%

N/A

Free Cash Flow

CA$451.00K

+132.9%

Operating Cash Flow

CA$451.00K

+135.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LVCLFAlgorae Pharmaceuticals Limited
$0.01+0.00%
ALRTFALR Technologies Inc.
$0.02+21.60%
LUFFFHerbal Dispatch Inc.
$0.03+24.73%
CHHEChina Health Industries Holdings, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$107.08-5.34%
NVDANvidia
$230.48-2.94%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
BITOProShares Trust - ProShares Bitcoin ETF
$10.93-1.88%

Questions About VPHIF

What is the current price of Valeo Pharma?

Valeo Pharma is trading at $0.00 per share.

What is the 52-week range for Valeo Pharma?

Over the past 52 weeks, Valeo Pharma has traded between $0.00 and $0.05.

How much debt does Valeo Pharma have?

As of the most recent reporting period, Valeo Pharma reported total debt of CA$47.37M.

How much cash does Valeo Pharma have on hand?

Valeo Pharma reported CA$5.40M in cash and cash equivalents in its most recent financial results.

What is Valeo Pharma’s dividend yield?

Valeo Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services